{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T01:58:31Z","timestamp":1755223111548,"version":"3.43.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014476","name":"Pfizer BV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.urolonc.2025.04.005","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T16:06:54Z","timestamp":1748707614000},"page":"520.e9-520.e18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Avelumab and taxol chemotherapy in platinum-refractory or ineligible metastatic urothelial carcinoma (AVETAX trial)"],"prefix":"10.1016","volume":"43","author":[{"given":"Rohan","family":"Garje","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9545-8769","authenticated-orcid":false,"given":"Aditya","family":"Ravindra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bilal","family":"Rahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathew","family":"Kroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey S.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Bonner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vignesh T.","family":"Packiam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Mott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousef","family":"Zakharia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.04.005_bib0001","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/EDBK_201193","article-title":"Systemic therapy for advanced urothelial carcinoma: current standards and treatment considerations","volume":"38","author":"Dietrich","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"13","key":"10.1016\/j.urolonc.2025.04.005_bib0002","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.urolonc.2025.04.005_bib0003","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","article-title":"Avelumab, an anti-programmed death-ligand 1 antibody, In patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study","volume":"35","author":"Apolo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.04.005_bib0004","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(17)30239-5","article-title":"Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial","volume":"18","author":"Heery","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2025.04.005_bib0005","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.urolonc.2025.04.005_bib0006","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.urolonc.2025.04.005_bib0007","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"CheckMate 901 trial investigators. Nivolumab plus Gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.urolonc.2025.04.005_bib0008","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.urolonc.2025.04.005_bib0009","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.urolonc.2025.04.005_bib0010","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"EV-302 trial investigators. Enfortumab Vedotin and Pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.urolonc.2025.04.005_bib0011","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/annonc\/mdy551","article-title":"Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors","volume":"30","author":"Heinhuis","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.04.005_bib0012","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2025.04.005_bib0013","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.juro.2006.08.078","article-title":"Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines","volume":"177","author":"Loskog","year":"2007","journal-title":"J Urol"},{"issue":"19","key":"10.1016\/j.urolonc.2025.04.005_bib0014","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.3390\/cancers15194886","article-title":"Current and emerging strategies to treat urothelial carcinoma","volume":"15","author":"Rani","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"15","key":"10.1016\/j.urolonc.2025.04.005_bib0015","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1158\/1078-0432.CCR-20-4574","article-title":"Myeloid cell-associated resistance to PD-1\/PD-L1 blockade in urothelial cancer revealed through bulk and single-cell RNA sequencing","volume":"27","author":"Wang","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.urolonc.2025.04.005_bib0016","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1200\/JCO.1997.15.5.1853","article-title":"Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma","volume":"15","author":"McCaffrey","year":"1997","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.04.005_bib0017","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/21645515.2018.1551671","article-title":"Product review: avelumab, an anti-PD-L1 antibody","volume":"15","author":"Collins","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.urolonc.2025.04.005_bib0018","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1158\/2767-9764.CRC-23-0436","article-title":"Low-dose Paclitaxel with Pembrolizumab enhances clinical and immunologic responses in platinum-refractory urothelial carcinoma","volume":"4","author":"Bitting","year":"2024","journal-title":"Cancer Res Commun"},{"issue":"6","key":"10.1016\/j.urolonc.2025.04.005_bib0019","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3892\/mco.2016.821","article-title":"Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer","volume":"4","author":"Sideris","year":"2016","journal-title":"Mol Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.04.005_bib0020","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986","volume":"30","author":"De Santis","year":"2012","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.urolonc.2025.04.005_bib0021","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.urolonc.2025.04.005_bib0022","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of Trastuzumab Deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.04.005_bib0023","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.annonc.2024.01.002","article-title":"TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes","volume":"35","author":"Loriot","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.04.005_bib0024","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000604","article-title":"Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy","volume":"8","author":"Haanen","year":"2020","journal-title":"J Immunother Cancer"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925001292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925001292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T11:35:24Z","timestamp":1754912124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925001292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1078143925001292"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.04.005","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avelumab and taxol chemotherapy in platinum-refractory or ineligible metastatic urothelial carcinoma (AVETAX trial)","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}